Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.01.7038 on September 26 2005

Journal of Clinical Oncology, Vol 23, No 30 (October 20), 2005: pp. 7594-7603
© 2005 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malcovati, L.
Right arrow Articles by Cazzola, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malcovati, L.
Right arrow Articles by Cazzola, M.

Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making

Luca Malcovati, Matteo Giovanni Della Porta, Cristiana Pascutto, Rosangela Invernizzi, Marina Boni, Erica Travaglino, Francesco Passamonti, Luca Arcaini, Margherita Maffioli, Paolo Bernasconi, Mario Lazzarino, Mario Cazzola

From the Division of Hematology and the Department of Internal Medicine, University of Pavia Medical School; and Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy

Address reprint requests to Mario Cazzola, MD, Division of Hematology, IRCCS, Policlinico San Matteo, 27100 Pavia, Italy; e-mail: mario.cazzola{at}unipv.it

PURPOSE: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and life expectancy in these groups as a basis for clinical decision making.

PATIENTS AND METHODS: Four hundred sixty-seven patients who were diagnosed as having de novo MDS at the Division of Hematology, University of Pavia (Pavia, Italy), between 1992 and 2002, were evaluated retrospectively for clinical and hematologic features at diagnosis, overall survival (OS), and progression to leukemia (leukemia-free survival).

RESULTS: Significant differences in survival were noted between patients with refractory anemia (RA), refractory cytopenia with multilineage dysplasia, RA with excess blasts, type 1 (RAEB-1), and RAEB-2. The effect of demographic factors on OS was observed in MDS patients without excess blasts (age, P = .001; sex, P = .006), as in the general population. The mortality of RA patients 70 years or older did not differ significantly from that of the general population (SMR, 1.62; P = .06). Cytogenetics was the only International Prognostic Scoring System variable showing a prognostic value in MDS classified into WHO subgroups. Transfusion-dependent patients had a significantly shorter survival than patients who did not require transfusions (P < .001). Developing a secondary iron overload significantly affected the survival of transfusion-dependent patients (P = .003).

CONCLUSION: These data show that the WHO classification of MDSs has a relevant prognostic value. This classification, along with cytogenetics, might be useful in decisions regarding transplantation. MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable.

Supported by grants to M.C. from Associazione Italiana per la Ricerca sul Cancro and Fondazione Cariplo, Milan, Italy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
haematolHome page
A. A. Di Tucci, G. Matta, S. Deplano, A. Gabbas, C. Depau, D. Derudas, G. Caocci, A. Agus, and E. Angelucci
Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias
Haematologica, September 1, 2008; 93(9): 1385 - 1388.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo, M. T. Van Lint, M. Falda, F. Onida, M. Bernardi, A. P. Iori, A. Rambaldi, R. Cerretti, et al.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Blood, August 1, 2008; 112(3): 895 - 902.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. T. Bowen, P. Fenaux, E. Hellstrom-Lindberg, and T. de Witte
Time-Dependent Prognostic Scoring System for Myelodysplastic Syndromes Has Significant Limitations That May Influence Its Reproducibility and Practical Application
J. Clin. Oncol., March 1, 2008; 26(7): 1180 - 1180.
[Full Text] [PDF]


Home page
JCOHome page
L. Malcovati, M. Cazzola, and U. Germing
In Reply
J. Clin. Oncol., March 1, 2008; 26(7): 1181 - 1182.
[Full Text] [PDF]


Home page
BloodHome page
A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry
Blood, February 1, 2008; 111(3): 1067 - 1077.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Blood, January 15, 2008; 111(2): 574 - 582.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Platzbecker, G. Ehninger, and M. Bornhauser
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation
Blood, October 15, 2007; 110(8): 3083 - 3083.
[Full Text] [PDF]


Home page
JCOHome page
L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al.
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Y. Kordasti, W. Ingram, J. Hayden, D. Darling, L. Barber, B. Afzali, G. Lombardi, M. W. Wlodarski, J. P. Maciejewski, F. Farzaneh, et al.
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Blood, August 1, 2007; 110(3): 847 - 850.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
C. Rose, O. Ernst, B. Hecquet, P. Maboudou, P. Renom, M. P. Noel, I. Yakoub-Agha, F. Bauters, and J. P. Jouet
Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantation
Haematologica, June 1, 2007; 92(6): 850 - 853.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Melchert and A. F. List
Management of RBC-Transfusion Dependence
Hematology, January 1, 2007; 2007(1): 398 - 404.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Kuendgen, C. Strupp, M. Aivado, B. Hildebrandt, R. Haas, N. Gattermann, and U. Germing
Myelodysplastic Syndromes in Patients Younger Than Age 50
J. Clin. Oncol., December 1, 2006; 24(34): 5358 - 5365.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
F. Salvi, D. Gioia, D. Cilloni, E. Audisio, M. Bonferroni, G. Cametti, A. Darbesio, S. D'Ardia, C. Dellacasa, D. Ferrero, et al.
Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes.
Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2622 - 2622.
[Abstract] [PDF]


Home page
NEJMHome page
A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone, et al.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
N. Engl. J. Med., October 5, 2006; 355(14): 1456 - 1465.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes
Blood, August 1, 2006; 108(3): 1037 - 1044.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. W. Vardiman
Hematopathological Concepts and Controversies in the Diagnosis and Classification of Myelodysplastic Syndromes
Hematology, January 1, 2006; 2006(1): 199 - 204.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online